AI Summary
5 min readHims & Hers: Disrupting Healthcare by Starting Where the System Won't
Andrew Dudum, co-founder and CEO of Hims & Hers, built a telehealth company that now treats 10,000 to 15,000 patients per day globally. The company went public in 2021, just three years after founding, and has since become a major force in GLP-1 weight loss medications, sexual health, hair loss, and mental health. But the founding insight was not about scale or disruption. It was about the question patients ask when the doctor is already leaving the room.
The Wedge Strategy
Dudum started Hims in 2017 after noticing a pattern doctors described to him: patients would come for an annual appointment, answer all the questions, and then, as the doctor was walking out, say "one more thing." That one more thing was always the real reason they came — hair loss, erectile dysfunction, weight concerns, mental health. These were the conditions that affected people daily, that shaped their confidence and relationships, but that the healthcare system was structurally bad at addressing.
Continue reading the full summary in the app — free to try.
Read Full Summary →Free • No credit card required
Never miss an episode of Prof G Markets
Get every new episode summarized in your inbox — free, ~5 minutes to read.
No spam. Unsubscribe anytime.
What you'll learn
- 1 (01:46) **Founding Story & Stigmatized Entry Point** - Andrew Dudum explains why Hims started with stigmatized conditions like hair loss and ED, using them as conversation starters to activate consumers.
- 2 (04:44) **Why Stigmatized Conditions Were the Wedge** - Dudum elaborates on the strategy of normalizing uncomfortable conversations to build trust and expand care.
- 3 (09:20) **Young Male Health Crisis as a Market Insight** - Dudum discusses the isolation and confidence issues driving demand among young men, and how the brand normalizes uncomfortable topics.
- 4 (12:02) **Going Public: Strategy and Pressure Cooker** - Dudum explains the intentional decision to take Hims public via SPAC in 2021, just three years after founding.
- 5 (16:54) **Managing Stock Volatility and Team Morale** - Dudum shares how he keeps the team focused on the mission despite wild stock price swings.
- 6 (23:43) **GLP-1 Entry: Compounding, Shortage, and Price Pressure** - Dudum walks through Hims' entry into the weight loss market, the regulatory framework for compounding, and the resulting price war.
- 7 (30:48) **Industry Impact and Partnership Shift** - Dudum explains how Hims' pressure forced the entire GLP-1 industry to adapt, leading to partnerships with Novo Nordisk and Eli Lilly.
+ Full timestamped outline available in the app
Guests on this episode
Show Notes
Ed Elson sits down with Andrew Dudum, co-founder and CEO of Hims & Hers, to discuss why the company went public so early, how it made GLP-1s more affordable, and whether healthcare regulation has gone too far. They also explore why Hims & Hers chose to disrupt the system instead of working within it.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
More from this podcast
Prof G Markets →